

1

2 **Analysis and evaluation of blood screening**
3 **testing strategies in Nagqu, Tibet: one of**
4 **the highest cities in world**

5

6

7

8 **Liang Zang¹, Lei Zhou¹, Yaxin Fan^{1*}, Xiaohua Liang¹, Ji Duo², Hao Lin²,**
9 **Rui Bai², Mei Yang², Chao Dan²**

10

11

12 ¹ **Dalian Blood Center, Dalian, Liaoning, China**

13 ² **Nagqu Central Blood Station, Nagqu, Tibet, China**

14

15 *** Corresponding author**

16 **Email: yaxinfan@163.com**

17

18 **Abstract**

19 The aim of this study was to evaluate the performance of blood screening
20 strategies in Nagqu City, with a focus on serological and nucleic acid testing
21 effectiveness. Analysis of blood donation data from 2017 to 2023 revealed a
22 gradual increase in local blood donation rates, but the rate of unqualified
23 donations remained higher than the national average. Serological performance
24 verification showed good repeatability and precision, but improvements are
25 needed in the accuracy of certain markers. Nucleic acid performance
26 verification demonstrated excellent detection capability for low viral load HBV
27 infections. The conclusion highlights significant progress in the screening
28 strategies of Nagqu City, with the nucleic acid testing system showing
29 outstanding performance. The findings provide valuable insights for blood
30 screening in other high-altitude regions.

31 **Introduction**

32 Nagqu City, nestled in the northern part of the Tibet Autonomous Region
33 in China on the awe-inspiring Tibetan Plateau, stands as one of the highest
34 cities on Earth, boasting an average elevation of approximately 4,500 meters
35 (14,764 feet) above sea level[1]. Its population of 504,838 has transformed the
36 city into a crucial trade and commercial hub, fostering vital connections
37 between various Tibetan regions and neighboring countries[2]. Nevertheless,
38 the delivery of healthcare services, especially blood donation screening, faces
39 formidable challenges due to the city's geographical remoteness, limited
40 infrastructure, and the demanding high-altitude conditions it presents[3].

41 A significant stride towards improving blood donation and healthcare
42 services in the region occurred in 2017 with the establishment of a blood
43 station in Nagqu City. However, this unique city's population demographics
44 and high-altitude environment introduce distinct challenges that demand

45 careful consideration for ensuring effective and reliable blood screening and
46 donation procedures[4-9].

47 Given Nagqu City's remote location and limited infrastructure, the
48 validation and evaluation of laboratory blood testing systems, including
49 serological testing and nucleic acid testing (NAT), assume paramount
50 importance[10]. This validation entails assessing the accuracy, sensitivity, and
51 specificity of screening methods for detecting infectious diseases and
52 Transfusion-Transmissible Infections (TTIs), such as Hepatitis B virus (HBV),
53 Hepatitis C virus (HCV), Human Immunodeficiency Virus (HIV), and Syphilis.
54 Strict adherence to relevant regulations, such as the 'China Blood Bank
55 Quality Management Standards,' 'China Blood Bank Laboratory Quality
56 Management Standards,' and 'China Blood Technical Operating Procedures
57 (2019 edition)' [11-13], ensures the provision of a safe and adequate blood
58 supply to meet the healthcare needs of the local population.

59 In pursuit of evaluating the efficacy of current blood screening strategies,
60 this study meticulously analyzes blood screening results obtained from the
61 Nagqu City blood station laboratory over several years, with a primary focus on
62 comprehending the epidemiological trends of TTIs among the local donor
63 population. The profound insights into the prevalence and distribution of TTIs
64 will facilitate the identification of potential risks and areas for refining screening
65 strategies, thereby ensuring a safe blood supply and mitigating the
66 transmission of infectious diseases[14]. Furthermore, the study scrutinizes the
67 External Quality Assessment (EQA) results of the Nagqu blood station to
68 assess the laboratory's performance and accuracy in conducting blood
69 screening tests. This rigorous evaluation bolsters the reliability and
70 consistency of screening procedures, while also pinpointing any factors that
71 could impact result quality.

72 Through this comprehensive evaluation of current blood screening

73 strategies, the ultimate aim of this study is to refine and optimize the screening
74 protocols, ensuring their unwavering effectiveness and reliability. In doing so,
75 this endeavor seeks to enhance the safety of the blood supply in Nagqu City
76 and potentially engender valuable insights applicable to other high-altitude
77 regions worldwide grappling with similar challenges.

78 **Materials and methods**

79 **Sample Collection**

80 A total of 3,585 blood samples were collected from donors in Nagqu City
81 using standard procedures from September 1, 2017 to July 30, 2023. The
82 informed consents were duly obtained from all participants. Furthermore,
83 ethical approval was obtained from the Ethics Committee of the Dalian Blood
84 Center (LL-202202). The screening process involved specific testing
85 equipment for serological and nucleic acid testing.

86 The serological test performance verification (PV) serum panels included
87 HBsAg Serum Panel, HCV Ab Serum Panel, HIV-1 Ab Serum Panel, and TP
88 Ab Serum Panel. Each panel consisted of 20 positive samples, 20 negative
89 samples, 5 analytical sensitivity samples, and a set of precision verification
90 samples. The HIV-1 P24 Serum Panel included 10 positive samples, 20
91 negative samples, 10 analytical sensitivity samples, and a set of precision
92 verification samples. All serum panels were provided by Control Standard Co.,
93 Ltd.(Beijing, China). Blood Screening Four-Item Quality Control Samples and
94 Negative Quality Control Samples were provided by Control Standard Co.,
95 Ltd.(Beijing, China).

96 The NAT PV serum panels included the NAT Serum Panels C to G
97 (analytical sensitivity verification panels) included a total of 30 samples, with
98 HBV genotype C samples (C2 to C6) having concentrations of 25, 12, 6, 3, and
99 1.5 IU/mL, HCV subtype 2a samples (D2 to D6) having concentrations of 170,
100 85, 40, 20, and 10 IU/mL, HIV genotype CRF07_BC samples (E2 to E6)

101 having concentrations of 210, 105, 50, 25, and 12.5 IU/mL, HCV subtype 1b
102 samples (F2 to F6) having concentrations of 140, 70, 35, 17, and 8.5 IU/mL,
103 and HCV subtype 6a samples (G2 to G6) having concentrations of 220, 110,
104 55, 27, and 13 IU/mL. The panel also included 5 negative control samples. The
105 NAT evaluation serum panel A consisted of a total of 46 samples, with each
106 numbered as 3 vials, and each sample having 3 mL. All NAT serum panels
107 were provided by the National Center for Clinical Laboratories (NCCL).

108 **Testing Equipment and Reagents**

109 For serological testing, the ELISA method was used with the Aikang
110 URANUS AE 158 enzyme immunoassay system produced by Shenzhen
111 Aikang Biotechnology Co., Ltd. For nucleic acid testing, the DaAn Gene
112 DA3500S Nucleic Acid Extraction System from Guangzhou, China, and the
113 Aoyu AGS4800 PCR Amplification System from Hangzhou, China, were
114 employed.

115 Various diagnostic kits were used for specific tests:

116 HBsAg (Hepatitis B Surface Antigen) diagnostic kit: InTec Products, Inc.
117 (Xiamen, China), WANTAI BioPharm, Co., Ltd. (Beijing, China)

118 HCV (Hepatitis C Virus) antibody diagnostic kit: WANTAI BioPharm, Co.,
119 Ltd. (Beijing, China), Livzon Pharmaceutical Group Inc. (Zhuhai, China)

120 HIV (Human Immunodeficiency Virus) antibody diagnostic kit: WANTAI
121 BioPharm, Co., Ltd. (Beijing, China), Livzon Pharmaceutical Group Inc.
122 (Zhuhai, China)

123 Treponema pallidum (Syphilis) antibody diagnostic kit: InTec Products, Inc.
124 (Xiamen, China), WANTAI BioPharm, Co., Ltd. (Beijing, China)

125 Nucleic Acid Extraction: DaAn Blood Screening HBV, HCV, and HIV-1
126 Virus Nucleic Acid Test Kit from DAAN Gene (Guangzhou, China)

127 All testing reagents and kits were selected based on their suitability for
128 detecting specific markers and pathogens related to Hepatitis B, Hepatitis C,

129 HIV, and syphilis. The testing procedures and methods followed the
130 instructions provided by the manufacturers.

131 **Screening Strategy**

132 The serological markers were tested using different reagents, and each
133 marker was tested once. Single-Side Reactivity: If a single-side reagent
134 reaction was observed, a necessary repeat test was conducted to confirm the
135 result. If the repeated test still showed reactivity, the sample was considered
136 unqualified for single-side reactivity. Dual-Side Reactivity: If both side reagents
137 showed reactivity simultaneously, the sample was considered unqualified for
138 both sides. A non-reactive result in the nucleic acid test was considered
139 qualified, while a reactive result was deemed unqualified.

140 Both serological testing and NAT were conducted simultaneously, and
141 blood donations with qualified results for both tests were released.

142 **Serological Test Validation Procedure**

143 **Reproducibility**

144 Each Blood Screening Four-Item Quality Control Sample and Blood
145 Screening Negative Quality Control Sample were tested 10 times. All 20 test
146 results can not appear more than 1 negative/positive control does not meet the
147 manufacturer's requirements.

148 **Precision**

149 The precision verification samples of PV serum panels was tested within
150 one day. The CV of variation of intra-batch imprecision should be less than
151 15%.

152 **Sensitivity and Specificity**

153 The PV serum panels were applied and tested according to the
154 instructions. All samples within the blood screening panel were tested within
155 one day. The sensitivity and specificity are calculated based on the detection
156 results.

157 **Compliance**

158 The test results of laboratory samples participating in NCCL were
159 analyzed, the consistency of laboratory test results and NCCL target value
160 results was compared, and the coincidence rate of detection method was
161 calculated.

162 **Determination of Limit of Detection (LOD)**

163 Sensitivity samples from PV serum panels were subjected to serial
164 dilution. For each individual assay, three different concentrations were
165 prepared and subjected to 20 repeated tests. The LOD for each assay was
166 calculated as the lowest concentration at which 95% of the results yielded a
167 Signal-to-Cut-off ratio (S/CO) ≥ 1 .

168 **NAT Validation Procedure**

169 **Analytical Sensitivity**

170 The laboratory evaluated the analytical sensitivity using NAT Serum
171 Panels C to G provided by NCCL. The samples covered the minimum
172 detection limits declared in the reagent instructions (HBV/HCV/HIV ≤ 100
173 IU/mL). Before testing, the samples were thawed at room temperature and
174 mixed thoroughly by vortexing for 30 seconds or inverting 30 times. Each
175 sensitivity verification panel was tested over three days, with each
176 concentration tested in at least 6 replicates per day, totaling no less than 20
177 replicates over the three days. SPSS 20.0 was used for PROBIT analysis to
178 assess the LOD and the two-sided 95% CI for each virus.

179 **Precision**

180 The laboratory assessed precision using standard materials with
181 concentrations less than 3 times the LOD for HBV DNA(25 IU/mL), HCV RNA
182 (170 IU/mL), HIV-1 RNA (105 IU/mL) and negative controls provided by the
183 NCCL. Each material was tested 20 times, and the results were collected to
184 calculate the system's precision.

185 **Cross-Contamination**

186 To evaluate cross-contamination, five positive standard materials (C2 to
187 G2) from the Analytical Sensitivity Serum Panel were placed together with five
188 negative standard materials from the NAT Serum Panels in a single-test mode
189 using the sample rack. The laboratory analyzed the detection results of both
190 positive and negative standard materials to assess any cross-contamination.

191 **Consistency**

192 The laboratory analyzed the test results of laboratory samples
193 participating in the NCCL EQA. The coincidence rate between the laboratory's
194 test results and the NCCL results was calculated to evaluate the system's
195 consistency.

196 **Detecting low viral load HBV infections**

197 46 samples with low concentration of HBV DNA from NAT Serum A
198 provided by the NCCL. The samples were remelted at room temperature
199 before detection, swirled for 30 seconds or reversed for 30 times, thoroughly
200 mixed, and centrifuged for 1000-1500g for 5 minutes. All samples were tested
201 by single-sample test, the first test was only once, and the second test was
202 double-hole retest.

203 **Results**

204 **Innovations and Challenges in Blood Donation**

205 Despite facing geographical remoteness and limited infrastructure, Nagqu
206 City has made remarkable efforts to overcome challenges in healthcare
207 delivery and blood donation. Innovations in healthcare include the
208 implementation of telemedicine, providing remote consultations and medical
209 services, along with the deployment of mobile healthcare units to extend
210 essential care to remote communities. Community education and engagement
211 have played a pivotal role in promoting blood donation, with awareness
212 campaigns and blood drives leading to a significant increase in donors. As

213 indicated in Table 1, these initiatives have contributed to an overall rise in
 214 blood donations over the years, showcasing the active participation of the local
 215 population in blood donation. However, despite progress in healthcare and
 216 blood donation, challenges persist. Factors such as religious beliefs among
 217 ethnic minorities and seasonal weather conditions contribute to blood
 218 shortages in Nagqu City. Severe weather conditions from October to April,
 219 including snowstorms, windstorms, hailstorms, and flooding, significantly
 220 impact the accessibility and availability of blood donations. These unique
 221 challenges necessitate further efforts to address the issue of blood shortages
 222 while considering the specific religious and climatic factors in the region.

223 Table 1 and Fig 1 provide data on the number and rate of unqualified
 224 donations over the years, demonstrating the effectiveness of serological
 225 testing strategies. The rate of unqualified donations has generally decreased
 226 over time, indicating an improvement in the effectiveness of serological testing
 227 strategies. However, when compared to the national average rates from the
 228 2021 National Research on Blood Screening, Nagqu City's rates of unqualified
 229 donations for various blood screening markers consistently exceed the
 230 national average. This highlights the challenge of ensuring a safe and
 231 adequate blood supply in Nagqu City, given the high prevalence of TTIs,
 232 particularly HBV.

233

234 **Table1. Number of Donations and Number (Rate) unqualified Donations**
 235 **in Nagqu City from 2017 to 2023**

Year	Donations	Serological Test					NAT		
		ALT	HBsAg	Anti-HCV	Anti-HIV	Anti-TP	HBV-DNA	HCV-RNA	HIV-RNA
2017	35	3 (8.57%)	1 (2.86%)	1 (2.86%)	1 (2.86%)	0	0	0	0
2018	186	11 (5.91%)	0	0	2 (1.08%)	2 (1.08%)	3 (1.61%)	0	0
2019	288	17 (5.90%)	5 (1.74%)	0	1 (0.35%)	1 (0.35%)	3 (1.04%)	0	0
2020	764	36 (4.71%)	4 (0.52%)	0	0	13 (1.70%)	4 (0.52%)	0	0
2021	1117	48 (4.30%)	5 (0.45%)	1 (0.09%)	2 (0.18%)	8 (0.72%)	6 (0.54%)	0	0
2022	695	15 (2.16%)	6 (0.86%)	0	1 (0.14%)	7 (1.01%)	7 (1.01%)	1 (0.14%)	0
2023	500	13 (2.60%)	3 (0.60%)	0	1 (0.20%)	8 (1.60%)	5 (1.00%)	0	1 (0.20%)

Total	3585	143 (3.99%)	24 (0.67%)	2 (0.06%)	8 (0.22%)	39 (1.09%)	28 (0.78%)	1 (0.03%)	1 (0.03%)
National Average Rate (2021)		0.75%	0.46%	0.13%	0.12%	0.30%		0.13%	

236 Note: The data access period was from August 1, 2023. The data was collected within the timeframe from
 237 September 1, 2017, to June 31, 2023. After data collection, authors had access to information that could identify
 238 individual participants.

239

240 **Fig 1. Time trend for prevalence of ALT, HBV, HCV, HIV, and syphilis among donations**
 241 **in Nagqu of China, 2017–2023**

242

243 Performance Verification of Blood Screening

244 To further analyze the performance of blood screening strategies in
 245 Nagqu City, we conducted performance verification for both serological and
 246 nucleic acid testing procedures. The results, presented in Tables 2, 3 and 4,
 247 provide valuable insights into the reliability and accuracy of the testing
 248 methods.

249 Table 2 demonstrates the Serological Testing Performance Verification for
 250 TTIs in Nagqu City. The results indicate reliable repeatability, with all markers
 251 achieving 100% consistency in repeated testing. HIV p24 Ag (WANTAI) and
 252 TP Ab (WANTAI) showed higher precision with CV values of 4.04% and 4.3%,
 253 respectively, while HCV Ab (Livzon) and HBsAg (InTec) exhibited higher CV
 254 values of 14.30% and 13.87%, but still below the acceptable limit of 15%.
 255 Sensitivity and specificity were 100% for all markers. The EQA activities in
 256 2021 and 2022 involved multiple assessments, and all testing items, including
 257 HBsAg, HCV Ab, HIV-1 Ab, and TP Ab, achieved 100% compliance, indicating
 258 high levels of accuracy and precision in the laboratory's testing procedures
 259 during these years.

260

261 **Table 2. Serological Testing Performance Verification for TTIs in Nagqu**
 262 **City**

Testing	Test	Reproducibility	Precision	Sensitivity	Specificity	Compliance
---------	------	-----------------	-----------	-------------	-------------	------------

Marker	Reagent					
HBsAg	InTec	100%	13.87%	100%	100%	-
	WANTAI	100%	10.80%	100%	100%	100%
HCV Ab	WANTAI	100%	5.02%	100%	100%	100%
	Livzon	100%	14.30%	100%	100%	-
HIV-1 Ab	WANTAI	100%	8.18%	100%	100%	100%
	Livzon	100%	12.40%	100%	100%	-
HIV-1 p24	WANTAI	100%	4.04%	100%	100%	-
	Livzon	100%	8.20%	100%	100%	-
TP Ab	InTec	100%	7.54%	100%	100%	-
	WANTAI	100%	4.30%	100%	100%	100%

263 Note: "-" indicating that the test was not performed.

264

265 Table 3 and Fig 2 present the LOD for serological blood screening
 266 markers. According to the results, the LOD for HBsAg detection was 0.2 IU/mL
 267 for both InTec and WANTAI. For HCV Ab detection, WANTAI and Livzon
 268 achieved LODs of 0.025 NCU/mL and 0.013 NCU/mL, respectively. The LOD
 269 for HIV-1 Ab detection with both WANTAI and Livzon was 0.25 NCU/mL. In the
 270 case of HIV-1 p24 detection, the LODs were 1.25 U/mL and 2.5 U/mL for
 271 WANTAI and Livzon, respectively. Notably, for TP Ab detection, both InTec
 272 and WANTAI exhibited relatively low LODs at 1.5 mIU/mL.

273

274 **Table 3. Serological Testing LOD for TTIs in Nagqu City**

Testing Marker	Test Reagent	Standard Concentrations	Test Results (S/CO)				
			Mean Values	SD	Maximum Values	Minimum Values	Detection Percentages
HBsAg	InTec	0.5 IU/mL	8.05	0.32	8.63	7.66	100%
		0.2 IU/mL	2.35	0.18	2.86	2.10	100%
		0.1 IU/mL	0.95	0.10	1.23	0.84	20%
	WANTAI	0.5 IU/mL	9.87	0.39	10.64	9.24	100%
		0.2 IU/mL	3.03	0.22	3.42	2.64	100%
		0.1 IU/mL	1.15	0.12	1.32	0.95	85%
HCV Ab	WANTAI	0.1 NCU/mL	7.51	0.30	7.98	7.09	100%
		0.05 NCU/mL	4.46	0.19	4.80	4.08	100%
		0.025 NCU/mL	1.64	0.28	2.22	1.24	100%
	Livzon	0.05 NCU/mL	4.79	0.23	5.04	4.23	100%

		0.025 NCU/mL	2.58	0.27	3.24	2.22	100%
		0.013 NCU/mL	1.32	0.12	1.64	1.15	100%
HIV-1 Ab	WANTAI	1 NCU/mL	5.89	0.26	6.26	5.44	100%
		0.5 NCU/mL	2.42	0.13	2.64	2.22	100%
		0.25 NCU/mL	1.50	0.10	1.68	1.34	100%
	Livzon	0.5 NCU/mL	5.40	0.19	5.88	5.06	100%
		0.25 NCU/mL	3.56	0.21	3.91	3.29	100%
		0.125 NCU/mL	1.14	0.11	1.33	0.96	90%
HIV-1 p24	WANTAI	5 U/mL	5.38	0.15	5.57	5.07	100%
		2.5 U/mL	2.60	0.31	3.24	2.27	100%
		1.25 U/mL	1.25	0.07	1.36	1.16	100%
	Livzon	10 U/mL	6.44	0.18	6.68	6.10	100%
		5 U/mL	2.54	0.26	3.07	2.24	100%
		2.5 U/mL	1.48	0.15	1.84	1.18	100%
TP Ab	InTec	6 mIU/mL	6.65	0.23	6.99	6.26	100%
		3 mIU/mL	3.44	0.18	3.69	3.08	100%
		1.5 mIU/mL	1.12	0.05	1.21	1.06	100%
	WANTAI	6 mIU/mL	6.57	0.30	6.99	5.96	100%
		3 mIU/mL	3.51	0.14	3.69	3.21	100%
		1.5 mIU/mL	1.47	0.09	1.59	1.32	100%

275 Note: Gray-shaded cells represent the lowest detectable concentrations, with a criterion of S/CO ≥ 1 being
 276 considered as a detectable result.

277

278 Fig 2. Detection Limits of Serological Blood Screening Markers in Nagqu City

279

280 Table 4 presents the Performance Verification of NAT for TTIs in Nagqu
 281 City. The results demonstrate reliable analytical sensitivity, with LODs within
 282 the declared limits for HBV, HCV, and HIV detection. The precision was
 283 satisfactory for most markers, with CV values below 5%, indicating good
 284 repeatability. The system exhibited excellent specificity, as
 285 cross-contamination was not observed. Additionally, the consistency analysis
 286 showed a 100% coincidence rate between the laboratory's results and the
 287 NCCL results, confirming the accuracy and reliability of the nucleic acid testing
 288 system used in Nagqu City.

289

290 **Table 4. Performance Verification of NAT for TTIs in Nagqu City**

TTIs Markers	Genotype	Average 95% LOD (95% CI) (IU/mL)	Reproducibility	Precision	Compliance
HBV DNA	HBV genotype C	8.29(5.88-20.55)	100%	2.01%	100%
	HCV subtype 2a	97.14(71-182.67)			
HCV RNA	HCV subtype 1b	176.64(136.41-270.98)	100%	3.18%	100%
	HCV subtype 6a	198.11(149.42-320.88)			
HIV-1 RNA	HIV-1 genotype CRF07_BC	40.52(30.26-85.92)	100%	4.25%	100%

291

292 **Evaluation of Blood Screening Strategies**

293 The evaluation of blood screening strategies aimed to assess the
294 performance and suitability of the Nagqu NAT system for nucleic acid
295 screening strategies. As shown in Table 5, all the samples from Serum Panel
296 A were tested negative for HBsAg using chemiluminescent immunoassay.
297 These samples were confirmed by the NCCL to be HBV DNA low
298 concentration samples. Among them, 18 samples showed reactive results in
299 the Roche NAT system, of which 8 samples were also reactive in our initial
300 screening, resulting in a screening positive concordance rate of 44.44%. In the
301 confirmatory retesting, 14 samples remained reactive, resulting in a
302 confirmatory positive concordance rate of 77.78%. Similarly, in the Haoyuan
303 NAT system, 22 samples showed reactive results, with 13 samples being
304 reactive in our initial screening, yielding a screening positive concordance rate
305 of 59.09%. In the confirmatory retesting, 13 samples remained reactive,
306 resulting in a confirmatory positive concordance rate of 59.09%. Among the 38
307 samples that tested positive for HBcAb in serological testing, our initial
308 screening yielded a detection rate of 47.37% (18/38), while the confirmatory
309 retesting had a detection rate of 68.57% (24/35). Three samples were not
310 retested due to insufficient sample volume. The results indicate the

311 performance of the Nagqu NAT system in detecting HBV DNA and its
 312 concordance with other NAT systems.

313 The results demonstrate the effectiveness of the nucleic acid testing
 314 system, particularly in detecting low viral load HBV infections. The system's
 315 adoption has proven to be more efficient in preventing the transmission of HBV
 316 through blood transfusions in high-prevalence regions like Nagqu City. The
 317 findings underscore the importance of NAT in maintaining a safe blood supply
 318 and reducing the risk of transfusion-transmitted HBV infections. Moreover, the
 319 testing strategy is also cost-effective and suitable for high-altitude regions with
 320 low donation volume, using a single-test mode. Despite the challenges posed
 321 by the high-altitude and dry climate of Nagqu City, the blood screening
 322 procedures have demonstrated minimal differences compared to the plains
 323 regions. The system exhibited excellent stability and accuracy, ensuring
 324 reliable blood screening results even under such environmental conditions.

325

326 **Table 5. Results of s Serum Panel A of HBV DNA low viral load samples**
 327 **tested in different NAT systems**

Sample ID	Testing Reagent	Test Results (Ct)	Nagqu NAT Results			Serological Test Results (NCCL) (Chemiluminescent Assay)				
			Initial Test (Ct)	Repeat Test 1 (Ct)	Repeat Test 2 (Ct)	HBsAg	HBsAb	HBeAg	HBeAb	HBcAb
NAT A 001	N/A	N/A	NR	NR	NR	NR	17.16	NR	NR	NR
NAT A 002	N/A	N/A	33.07	31.81	32.58	NR	NR	NR	NR	NR
NAT A 003	MPX	36.8	36.45	35.62	36.19	NR	NR	NR	NR	NR
NAT A 004	MPX	38.2	NR	NR	NR	NR	18.04	NR	NR	R
NAT A 006	MPX	36.3	NR	34.55	NR	NR	NR	NR	NR	R
NAT A 007	MPX	36.4	36.82	33.93	34.83	NR	NR	NR	NR	R
NAT A 009	MPX	35.9	35.97	36.68	NR	NR	NR	NR	R	R
NAT A 010	MPX	37.2	NR	35.51	NR	NR	NR	NR	R	R
NAT A 011	MPX	35	NR	36.21	36.50	NR	NR	NR	R	R
NAT A 012	MPX	39	NR	NR	NR	NR	NR	NR	R	R

NAT A 013	MPX	35.9	34.12	36.11	34.24	NR	256.5	NR	R	R
NAT A 014	MPX	30.6	32.02	31.37	31.79	NR	12.07	NR	NR	R
NAT A 015	MPX	34.9	33.86	35.73	35.57	NR	NR	NR	R	R
NAT A 016	MPX	37.2	NR	NR	NR	NR	NR	NR	NR	R
NAT A 017	MPX	30.4	33.14	32.05	31.53	NR	NR	NR	R	R
NAT A 018	MPX	36.5	NR	37.14	NR	NR	NR	NR	NR	R
NAT A 019	MPX	34.2	38.65	38.82	37.36	NR	NR	NR	R	R
NAT A 034	MPX	36.3	NR	36.77	36.45	NR	NR	NR	R	R
NAT A 037	MPX	37.8	NR	NR	36.33	NR	NR	NR	R	R
NAT A 044	MPX	34.9	NR	N/A	N/A	NR	NR	NR	R	R
NAT A 005	Haoyuan	37.8	NR	NR	36.16	NR	NR	NR	NR	NR
NAT A 008	Haoyuan	35.61	37.67	34.01	36.83	NR	NR	NR	R	R
NAT A 020	Haoyuan	41.53	NR	NR	NR	NR	NR	NR	R	R
NAT A 021	Haoyuan	41.37	NR	NR	NR	NR	NR	NR	NR	R
NAT A 022	Haoyuan	44.06	NR	NR	NR	NR	16.68	NR	R	R
NAT A 023	Haoyuan	40.74	36.37	36.68	35.33	NR	NR	NR	NR	R
NAT A 024	Haoyuan	40.91	36.14	NR	NR	NR	NR	NR	R	R
NAT A 025	Haoyuan	41.3	37.11	35.85	35.74	NR	NR	NR	NR	R
NAT A 026	Haoyuan	38.31	NR	44.19	36.72	NR	NR	NR	R	R
NAT A 027	Haoyuan	43.982	NR	NR	NR	NR	NR	NR	NR	R
NAT A 028	Haoyuan	43.557	NR	NR	NR	NR	88.99	NR	NR	R
NAT A 029	Haoyuan	40.138	36.62	39.43	35.90	NR	NR	NR	NR	R
NAT A 030	Haoyuan	38.304	37.08	35.42	35.98	NR	NR	NR	R	R
NAT A 031	Haoyuan	42.05	NR	NR	37.36	NR	68.66	NR	R	R
NAT A 032	Haoyuan	33.3	33.23	32.20	32.34	NR	37.8	NR	NR	R
NAT A 033	Haoyuan	41.35	44.29	36.14	NR	NR	NR	NR	NR	NR
NAT A 035	Haoyuan	39	37.50	NR	35.91	NR	NR	NR	R	R
NAT A 036	Haoyuan	36.22	35.03	34.42	34.59	NR	NR	NR	R	R
NAT A 038	Haoyuan	38.57	NR	36.10	36.40	NR	NR	NR	NR	R
NAT A 043	Haoyuan	38.65	37.95	NR	NR	NR	NR	NR	NR	NR
NAT A 045	Haoyuan	37.45	35.90	N/A	N/A	NR	NR	NR	NR	R
NAT A 046	Haoyuan	42.81	33.28	N/A	N/A	NR	87.2	NR	R	R

328 Note: The sample IDs used in this study were strictly internal and confidential, known only within the research group.

329 MPX: cobas® TaqScreen MPX Test Kit (v2.0) tested by Roche cobas s 201 system. Haoyuan: Haoyuan Biotech NAT

330 Kit for HBV/HCV/HIV -1 ((Real-time PCR) tested by Haoyuan ChiTaS BSS1200 NAT system. R: Reactive. NR:

331 Non-reactive. N/A: Untested. Parallel NAT system detection results data provided by NCCL.

332 Discussion

333 This study aimed to investigate the blood screening strategies in Nagqu

334 City, Tibet, with a specific emphasis on the performance of serological and

335 nucleic acid testing. Despite encountering distinctive challenges of

336 geographical remoteness, high-altitude hypoxia, and a dry climate, valuable
337 insights can be gleaned from the analysis of blood screening outcomes.

338 The effectiveness and reliability of blood screening have demonstrated
339 continuous improvement, as evidenced by a declining trend in the rate of
340 unqualified donations over time, indicating the enhanced effectiveness of
341 screening strategies (Table 1). However, it is crucial to note that Nagqu City's
342 rates of unqualified donations for various markers still exceed the national
343 average. The majority (58.13%, 143/246) of the unqualified blood donations
344 detected in laboratories were attributed to failing the ALT screening, which
345 may be related to the donors' liver function. However, it is more likely
346 associated with unhealthy lifestyle habits, such as poor diet, alcohol
347 consumption, and medication use. To ensure the effective utilization of blood
348 resources, the importance of pre-donation screening for ALT should be
349 emphasized. Notably, positive results for HBV were the primary reason for
350 donor deferral in TTIs tests, with 9.76% (24/246) attributed to HBsAg and
351 11.38% (28/246) to HBV-DNA. Additionally, *Treponema pallidum* (TP), which
352 causes syphilis, accounted for a significant proportion (15.85%, 39/246) of
353 unqualified donations. These findings align with prevailing trends observed in
354 other high-altitude regions of the Qinghai-Tibet Plateau but are considered
355 considerably high when compared to other developing countries[15-18].
356 Moreover, it is essential to acknowledge that the prevalence of HBV infection
357 remains alarmingly high in China, with approximately 100 million people
358 suffering from chronic HBV infection[19]. The high prevalence of HBV and
359 other infectious markers in the blood donor pool in this region emphasizes the
360 importance of stringent quality management and individual donation nucleic
361 acid detection protocols in blood banks to ensure blood safety and prevent
362 potential HBV transfusion transmission[20-22]. Efforts should be directed
363 towards implementing effective measures to reduce the number of unqualified

364 donations, continuing to monitor the local TTIs' prevalence trends, and
365 enhancing overall blood safety in this geographically challenging area[23, 24].
366 By addressing these challenges and implementing targeted interventions, the
367 blood screening system in Nagqu City can further improve its effectiveness
368 and contribute to safer and more reliable blood donations.

369 The challenging high-altitude, oxygen-deficient, and dry climate conditions
370 in Nagqu indeed present unique obstacles to the blood screening process.
371 However, the results of the performance verification (as detailed in Tables 2, 3
372 and 4) illustrate the reliability and accuracy of both serological and nucleic acid
373 testing procedures in overcoming these challenges. Across all markers, there
374 is a consistent demonstration of high levels of consistency, reproducibility,
375 sensitivity, and specificity, ensuring that results are both reliable and precise.
376 One of the critical parameters in evaluating the effectiveness and sensitivity of
377 diagnostic assays is the LOD for serological blood screening markers. This
378 study undertook a comprehensive investigation into the LODs for various
379 bloodborne pathogens, encompassing HBsAg, HCV Ab, HIV-1 Ab, HIV-1 p24,
380 and TP Ab, using different test reagents. Remarkably, the observed LOD of
381 0.2 IU/mL for HBsAg detection in Nagqu City stands out, as it is significantly
382 lower than the LODs reported in the literature for domestically produced test
383 reagents. Typically, these reported LODs are around 0.6-1 IU/mL [25, 26]. This
384 remarkable increase in sensitivity is particularly advantageous, especially in
385 regions where early detection of hepatitis B infection is of paramount
386 importance due to the high prevalence of this disease. The findings shed light
387 on the performance and capabilities of these assays in Nagqu City, Tibet,
388 under challenging environmental conditions.

389 In this study, the NAT system displayed excellent capability in detecting
390 HBV DNA, which is particularly beneficial in high-altitude regions with a high
391 prevalence of HBV transmission[27]. The adoption of the NAT system

392 effectively detects low viral load HBV infections, minimizing the risk of HBV
393 transmission through blood transfusions[28]. This finding is crucial in reducing
394 the risk of transfusion-transmitted HBV infections and emphasizes the
395 significance of NAT in maintaining a safe blood supply. Other regions can
396 learn from Nagqu City's NAT strategies to strengthen monitoring and
397 prevention measures for low viral load infections, further enhancing transfusion
398 safety.

399 The research findings indicate minimal differences in the blood screening
400 process between Nagqu and plains regions in China[29-33]. Furthermore, the
401 system demonstrated exceptional stability and accuracy, signifying significant
402 progress in adapting to the high-altitude and dry conditions. The adaptability
403 and performance of the blood screening system in challenging environmental
404 conditions are commendable, highlighting the commitment of healthcare
405 professionals in Nagqu City to ensuring safe and reliable blood donations.
406 Despite the unique challenges posed by the high-altitude and dry climate, the
407 blood screening process in Nagqu City has demonstrated remarkable
408 effectiveness and reliability. The successful implementation of the NAT system
409 and the consistent performance of serological testing underscore the
410 commitment to maintaining a safe blood supply and preventing
411 transfusion-transmitted infections. These research findings not only benefit
412 Nagqu City but also provide valuable insights and practical guidance for other
413 high-altitude regions facing similar challenges in blood screening and
414 transfusion safety.

415 In conclusion, this study provides a comprehensive evaluation of blood
416 screening strategies in Nagqu City, demonstrating the effectiveness and
417 reliability of the current procedures. The research also offers valuable insights
418 and practical implications for other geographically remote and high-altitude
419 regions, particularly in nucleic acid testing. Through continuous improvement

420 and optimization strategies, we can further enhance the quality of blood
421 screening, ensure transfusion safety, and provide beneficial experiences and
422 guidance for blood screening in similar regions. This study fills gaps in
423 knowledge and offers important references and practical value for improving
424 blood screening and enhancing transfusion safety in geographically remote
425 regions. Future research should explore blood screening strategies adapted to
426 high-altitude and dry conditions to provide broader significance for other
427 geographically remote regions.

428 **Acknowledgments**

429 We extend our heartfelt gratitude to the National Center for Clinical
430 Laboratories their invaluable support, including their high regard for this study,
431 provision of panel samples, and technical assistance. Our sincere appreciation
432 goes to the Tibetan government for their multifaceted support. Special
433 recognition is due to the dedicated staff members of the blood bank
434 laboratories, whose unwavering support during the experiments is highly
435 commendable.

436

437 **Author Contributions**

438 Conceptualization: Yaxin Fan

439 Data curation and analysis: Liang Zang, Lei Zhou, Ji Duo

440 Investigation: Liang Zang, Lei Zhou, Yaxin Fan, Xiaohua Liang, Ji Duo

441 Methodology: Liang Zang, Lei Zhou, Yaxin Fan, Xiaohua Liang, Ji Duo, Hao

442 Lin, Rui Bai, Mei Yang, Chao Dan

443 Project Administration: Liang Zang, Yaxin Fan, Xiaohua Liang
444 Resources: Liang Zang, Yaxin Fan
445 Supervision: Yaxin Fan, Xiaohua Liang
446 Writing: Liang Zang
447 Writing - Review & Editing: Liang Zang, Lei Zhou, Yaxin Fan, Xiaohua Liang, Ji
448 Duo, Hao Lin, Rui Bai, Mei Yang, Chao Dan.

449

450 **References**

- 451 1. Nagqu overview. Nagqu City People's Government. Available online:
452 http://www.naqu.gov.cn/nqsrnzf/c100075/list_tt.shtml (accessed on 28 July
453 2023).
- 454 2. Figures on 2020 Population Census of China. Seventh National Census
455 Leading Group Office of The State Council. China Statistics Press. ISBN
456 978-7-5037-9506-0.
- 457 3. Foggin PM, Torrance ME, Dorje D, Xuri W, Marc Foggin J, Torrance J.
458 Assessment of the health status and risk factors of Kham Tibetan pastoralists
459 in the alpine grasslands of the Tibetan plateau. *Soc Sci Med.* 2006
460 Nov;63(9):2512-32. <https://doi.org/10.1016/j.socscimed.2006.06.018> PMID:
461 16891047.
- 462 4. Lang M., Bilo G., Caravita S., Parati G. Blood pressure and high altitude:
463 Physiological response and clinical management. *Medwave.* 2021;21:e8194.
464 <http://doi.org/10.5867/medwave.2021.04.8194> PMID: 34037579.
- 465 5. Huamaní C, Sarmiento W, Cordova-Heredia G, Cruz-Huanca L,
466 Damian-Saavedra P, Antonio D. Prediction of blood viscosity based on usual
467 hematological parameters in a clinically healthy population living in a

- 468 high-altitude city. *High Alt Med Biol.* 2022 Mar;23(1):78-84.
469 <https://doi.org/10.1089/ham.2021.0165> PMID: 35271375.
- 470 6. Wang Y, Wang H, Chen Y, Xu N, Lee W, Lam WK. Pulmonary capacity,
471 blood composition and metabolism among coal mine workers in high- and
472 low-altitude aboveground and underground workplaces. *Int J Environ Res*
473 *Public Health.* 2022 Jul 7;19(14):8295. <https://doi.org/10.3390/ijerph19148295>
474 PMID: PMC9318192.
- 475 7. MacNutt MJ, Sheel AW. Performance of evacuated blood collection tubes at
476 high altitude. *High Alt Med Biol.* 2008 Fall;9(3):235-7.
477 <https://doi.org/10.1089/ham.2008.1027> PMID: 18800961.
- 478 8. Chandramoorthy HC, Bajunaid AM, Kariri HN, Al-Hakami A, Sham AA,
479 Al-Shahrani MBS, et al. Feasibility of cord blood bank in high altitude Abha:
480 preclinical impacts. *Cell Tissue Bank.* 2018 Sep;19(3):413-422.
481 <https://doi.org/10.1007/s10561-018-9687-0> PMID: 29460118.
- 482 9. Luo X, Feng L, Bai X, Zhu J, Zhao G, Wu M, et al. Continuous changes in
483 biological levels of complete blood count in a high altitude area of China.
484 *SAGE Open Med.* 2020 Jun 13;8:2050312120931334.
485 <https://doi.org/10.1177%2F2050312120931334> PMID: 32587693.
- 486 10. Andriessen JW, Breard M, Briggs L, Butch S, Distler P, Georgsen J, et al.
487 International society for blood transfusion guidelines for validation of
488 automated systems in blood establishments. *Vox Sang.* 2022
489 Dec;117(12):1420-45. <https://doi.org/10.1111/vox.13332> PMID: 36285799.
- 490 11. National Health Commission of the People's Republic of China. *China*
491 *Blood Bank Quality Management Standards.* April 25, 2006.
- 492 12. National Health Commission of the People's Republic of China. *China*
493 *Blood Bank Laboratory Quality Management Standards.* May 9, 2006.
- 494 13. National Health Commission of the People's Republic of China. *China*
495 *Blood Technical Operating Procedures.* May 8, 2019.

- 496 14. Folléa G, Garraud O, Tiberghien P. Blood transfusion: the challenges for
497 tomorrow? *Presse Med.* 2015 Feb;44(2):227-32.
498 <https://doi.org/10.1016/j.lpm.2014.06.038> PMID: 25578549.
- 499 15. Sun P, Zhu L, Ma L, Li C, Wang Z, Zhang R, et al. Blood service in a region
500 of China's Qinghai-Tibetan plateau. *Healthcare (Basel)*. 2023 Jul
501 5;11(13):1944. <http://doi.org/10.3390/healthcare11131944> PMID: 37444778;
502 PMCID: PMC10341248.
- 503 16. Shang G, Seed CR, Wang F, Nie D, Farrugia A. Residual risk of
504 transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.
505 *Transfusion*. 2007 Mar;47(3):529-39.
506 <https://doi.org/10.1111/j.1537-2995.2006.01146.x> PMID: 17319836.
- 507 17. Xuerong Yu, Weiyun Chen, Zhong Liu, Yuguang Huang. Safety and
508 current status of blood transfusion in China: an update. *Lancet Haematol.* 2016
509 Feb;3(2):e60-2. [https://doi.org/10.1016/S2352-3026\(16\)00010-7](https://doi.org/10.1016/S2352-3026(16)00010-7) PMID:
510 26853643.
- 511 18. Kafi-abad SA, Rezvan H, Abolghasemi H, Talebian A. Prevalence and
512 trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C
513 virus among blood donors in Iran, 2004 through 2007. *Transfusion*. 2009
514 Oct;49(10):2214-20. <https://doi.org/10.1111/j.1537-2995.2009.02245.x> PMID:
515 19527477.
- 516 19. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the
517 impact of hepatitis B vaccination among children born during 1992-2005 in
518 China. *J Infect Dis.* 2009 Jul 1;200(1):39-47. <https://doi.org/10.1086/599332>
519 PMID: 19469708.
- 520 20. El Ekiaby M, Lelie N, Allain JP. Nucleic acid testing (NAT) in high
521 prevalence-low resource settings. *Biologicals*. 2010 Jan;38(1):59-64.
522 <https://doi.org/10.1016/j.biologicals.2009.10.015> PMID: 20079664.

- 523 21. Chang L, Zhao J, Guo F, Ji H, Zhang L, Jiang X, et al. Demographic
524 characteristics of transfusion-transmitted infections among blood donors in
525 China. *BMC Infect Dis*. 2019 Jun;19(1):514.
526 <https://doi.org/10.1186/s12879-019-4044-x> PMID: 31185990.
- 527 22. Abdella S, Moshago Berheto T, Tolera G, Belete W, Deressa T, Feleke A,
528 et al. Sero-prevalence of transfusion transmittable infections: HIV, Hepatitis B,
529 C and *Treponema pallidum* and associated factors among blood donors in
530 Ethiopia: A retrospective study. *PLoS One*. 2020 Oct 29;15(10):e0241086.
531 <https://doi.org/10.1371/journal.pone.0241086> PMID: 33119668.
- 532 23. Raykar NP, Makin J, Khajanchi M, Olayo B, Munoz Valencia A, Roy N, et
533 al. Assessing the global burden of hemorrhage: The global blood supply,
534 deficits, and potential solutions. *SAGE Open Med*. 2021 Nov
535 10;9:20503121211054995. <https://doi.org/10.1177/20503121211054995>
536 PMID: 34790356.
- 537 24. Aneke JC, Okocha CE. Blood transfusion safety; current status and
538 challenges in Nigeria. *Asian J Transfus Sci*. 2017 Jan-Jun;11(1):1-5.
539 <https://doi.org/10.4103/0973-6247.200781> PMID: 28316432.
- 540 25. Yihe Xiong. Application of two domestic HBsAg ELISA diagnostic reagents
541 in blood screening. *Jilin Medical Journal*. 2012;(7):1398-9. [in Chinese]
- 542 26. Lianghua Wang, Xuqun Wu, Ziqian Bao, Yunlong Chen, Xianlin Ye,
543 Guifang Shang, et al. Comparison of HBsAg retest results by different ELISA
544 reagents. *Chin J Blood Transfusion*. 2007;(2):124-5. [in Chinese]
- 545 27. Wang Y, Wu Z, Yin YH, Rao SQ, Liu B, Huang XQ, et al. Blood service in
546 the Tibetan regions of Garzê and Aba, China: a longitudinal survey. *Transfus*
547 *Med*. 2017 Dec;27(6):408-12. <https://doi.org/10.1111/tme.12468> PMID:
548 28944508.
- 549 28. Chen J, Ou-Yang J, Xie G, Liang H, Fan Y, Gao R, et al. Problems and
550 challenges: development of blood transfusion services in Mainland China

551 within the context of health-care system reform. *Transfus Med.* 2019 Aug;
552 29(4):253-61. <https://doi.org/10.1111/tme.12618> PMID: 31359545.

553 29. Xiaoyan Han, Maili Zhang, Xu Feng, Miaomiao Xu. Performance
554 verification of nucleic acid testing project based on ISO 15189 . *Chin J Blood*
555 *Transfusion.* 2022 Jan;35(01):95-8. [in Chinese]

556 30. Li Zhan, Wenjie Yang, Zhiqiang Chen, Zhangping Fan. Performance
557 evaluation of a domestic blood nucleic acid detection system. *J Mol Diagn*
558 *Ther.* 2023 Mar;15(3):442-5. <http://doi.org/10.19930/j.cnki.jmdt.2023.03.003>

559 31. Kai Chen, Yinghui Wang, Zhifeng Yuan. Discussion on performance
560 validation of nucleic acid test system in blood station. *J Clin Hematol (China)*,
561 2022;35 (8) : 584-91. [in Chinese]

562 32. Junying Li, Yifang Wang, Wenchao Ge, Xu Wang, Jianhua Fang. The
563 performance validation of a nucleic acid test system before blood screening.
564 *Chin J Blood Transfusion.* 2019 Jan;32(1):73-5. [in Chinese]

565 33. Runkui Wei, Lin Yu, Shaobin Chen, Miaoling Deng, Jingwen Chen, Ziyi He.
566 Performance verification of an individual donation nucleic acid detection
567 system for blood. *Chin J Blood Transfusion.* 2022 Apr;35(4):449-52. [in
568 Chinese]